Search Result

Breast cancer (BC) is the most common cancer to be diagnosed in more than 100 nations and is the main reason why most women die from cancer. This article mainly reviewed the breast cancer in the worldwide and emphasizes on the burden of BC in developing countries. Different developing nations like Nigeria, Jordan, Fiji Islands, Bangladesh, Afghanistan, India, Pakistan, South Africa, Brazil, China etc. have shown higher death rates and their women are struggling highly with BC due to many factors: economically instability, poor infrastructure and unawareness. The incidence and mortality rates of respective regions and countries are described with comparison between developed and developing countries. In conclusion, there are various ways to detect and diagnose BC and reasons to show their dominance in certain regions of the world.

Some epidemiological studies have reported a relationship between thyroid dysfunctions and the risk of breast cancer’s giving the similarities between estrogen and thyroid function. This study was therefore aimed at evaluating the level of thyroid gland hormones, TSH and estrogen in breast cancer patients. A cross-sectional study was carried out in the month of September to November 2019. A total of 60 subjects attending breast cancer screening clinic of Federal Medical Center and Imo State University, Owerri were recruited for this study. The 60 subjects are between the ages of 20-60 years. The 60 subjects were divided into two groups: Group 1 (Test) consists of 30 females with breast cancer. Group 2 (Control) consists of 30 apparently healthy women with no breast cancer. Blood samples were collected, and the level of thyroid hormone and estrogen was determined. Data generated was then analysed using SPSS version 21. There was no significant difference (p=0.308 and p=0.626 respectively) in the mean value of T3 and T4 in breast cancer patients (3.42±0.07 and 1.41±0.15 respectively)µIU/ml when compared to Controls (3.11±0.64 and 1.35±0.23)µIU/ml. The mean value of TSH was significantly increased (p=0.02) in breast cancer patients (2.79±1.05)Pmol/ml when compared to controls (1.40±0.17)Pmol/ml. The mean value of estrogen was significantly increased (p=0.000) in breast cancer patients (540.39±66.70)pg/ml when compared to controls (222.10±58.09)pg/ml. There was a non significant negative correlation of serum estrogen with serum T3, and T4, (r= -0.253, p=0.682 and r=-0.107, p=0.864). There was a non significant positive correlation of serum estrogen with serum TSH (r=0.380, p=0.528). There is a strong association between breast cancer and serum concentrations of thyroid stimulating hormone and estrogen, but there is no alteration in TSH hormones in breast cancer.

Breast cancer, characterized by uncontrollable growth of abnormal breast cells forming tumors, can be fatal if unchecked, spreading throughout the body. Originating in breast milk ducts or lobules, its early stages pose no immediate threat, but invasive forms can metastasize to other organs. Its prevalence has surpassed lung cancer globally. Projections suggest 28.4 million cases by 2040. Treatment varies based on the individual, cancer type, and its spread, involving surgery, radiation, and medication. Natural plant products show promise as antitumor and anti-cancer agents, exhibiting reduced toxicity and resistance to conventional drugs. These products leverage antioxidant, anti-inflammatory, and immunomodulatory properties, influencing cancer cell behavior. Some studies highlight herbs\' potential in developing anti-cancer drugs. Notably, breast cancer\'s impact is significant in developing countries. Inadequate medical infrastructure and high treatment costs promote the use of natural products in these countries. Plant-based remedies offer a less toxic alternative, crucial in regions with limited access to conventional treatments. Understanding breast cancer and early diagnosis is critical in managing its impact. Therefore, this review delves into breast cancer intricacies and underscores natural plant products\' potential in mitigating the projected increase in breast cancer-related deaths.